U.S. markets open in 8 hours 47 minutes
  • S&P Futures

    3,644.75
    -9.50 (-0.26%)
     
  • Dow Futures

    29,178.00
    -107.00 (-0.37%)
     
  • Nasdaq Futures

    11,198.50
    -29.75 (-0.26%)
     
  • Russell 2000 Futures

    1,676.60
    -5.50 (-0.33%)
     
  • Crude Oil

    80.83
    -0.40 (-0.49%)
     
  • Gold

    1,670.10
    +1.50 (+0.09%)
     
  • Silver

    18.82
    +0.10 (+0.55%)
     
  • EUR/USD

    0.9809
    -0.0011 (-0.11%)
     
  • 10-Yr Bond

    3.7470
    -3.7470 (-100.00%)
     
  • Vix

    31.84
    +1.66 (+5.50%)
     
  • GBP/USD

    1.1107
    -0.0016 (-0.14%)
     
  • USD/JPY

    144.6490
    +0.2060 (+0.14%)
     
  • BTC-USD

    19,437.17
    -97.83 (-0.50%)
     
  • CMC Crypto 200

    444.04
    -1.94 (-0.44%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    25,836.79
    -585.26 (-2.22%)
     

1 Cancer Stock on Buyout Watch in 2022

·3 min read
1 Cancer Stock on Buyout Watch in 2022

The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.